Marshall & Sterling Wealth Advisors Inc. Takes $482,000 Position in Zoetis Inc. (NYSE:ZTS)

Marshall & Sterling Wealth Advisors Inc. acquired a new position in Zoetis Inc. (NYSE:ZTS - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 2,959 shares of the company's stock, valued at approximately $482,000.

Other institutional investors also recently made changes to their positions in the company. Callahan Advisors LLC grew its stake in shares of Zoetis by 90.4% during the fourth quarter. Callahan Advisors LLC now owns 13,105 shares of the company's stock valued at $2,135,000 after buying an additional 6,221 shares during the last quarter. CIBC Asset Management Inc boosted its holdings in Zoetis by 24.1% during the 4th quarter. CIBC Asset Management Inc now owns 237,369 shares of the company's stock valued at $38,617,000 after acquiring an additional 46,050 shares during the period. Pensionfund Sabic grew its position in Zoetis by 55.6% during the 4th quarter. Pensionfund Sabic now owns 11,200 shares of the company's stock worth $1,825,000 after acquiring an additional 4,000 shares during the last quarter. Schroder Investment Management Group lifted its position in Zoetis by 2.6% in the fourth quarter. Schroder Investment Management Group now owns 245,726 shares of the company's stock valued at $40,036,000 after purchasing an additional 6,169 shares during the last quarter. Finally, PFW Advisors LLC purchased a new stake in shares of Zoetis during the fourth quarter valued at approximately $1,764,000. Hedge funds and other institutional investors own 92.80% of the company's stock.

Zoetis Stock Up 0.8 %

Shares of NYSE:ZTS traded up $1.22 on Wednesday, hitting $156.65. 2,926,140 shares of the company traded hands, compared to its average volume of 2,484,978. The stock has a 50 day simple moving average of $158.73 and a 200-day simple moving average of $167.90. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09. The company has a market cap of $69.89 billion, a PE ratio of 28.64, a PEG ratio of 2.78 and a beta of 0.92. Zoetis Inc. has a 52 week low of $139.70 and a 52 week high of $200.33.

Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings results on Thursday, February 13th. The company reported $1.40 EPS for the quarter, beating analysts' consensus estimates of $1.37 by $0.03. The firm had revenue of $2.32 billion for the quarter, compared to analysts' expectations of $2.30 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. As a group, research analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be paid a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a yield of 1.28%. The ex-dividend date of this dividend is Monday, April 21st. Zoetis's dividend payout ratio is currently 36.56%.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on ZTS. Barclays upped their price target on shares of Zoetis from $242.00 to $244.00 and gave the company an "overweight" rating in a report on Friday, February 14th. Piper Sandler raised their target price on Zoetis from $200.00 to $205.00 and gave the stock an "overweight" rating in a research note on Thursday, February 27th. Stifel Nicolaus dropped their price objective on Zoetis from $180.00 to $165.00 and set a "buy" rating for the company in a report on Monday, April 14th. Morgan Stanley reduced their target price on Zoetis from $243.00 to $238.00 and set an "overweight" rating on the stock in a research note on Friday, February 14th. Finally, StockNews.com upgraded Zoetis from a "hold" rating to a "buy" rating in a report on Friday, March 7th. One analyst has rated the stock with a hold rating, ten have given a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat.com, Zoetis presently has an average rating of "Buy" and a consensus price target of $214.40.

Insider Activity

In other news, EVP Roxanne Lagano sold 326 shares of the firm's stock in a transaction on Monday, March 10th. The stock was sold at an average price of $170.00, for a total value of $55,420.00. Following the transaction, the executive vice president now directly owns 15,781 shares in the company, valued at $2,682,770. This trade represents a 2.02 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Willie M. Reed sold 1,210 shares of Zoetis stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total value of $201,029.40. Following the completion of the sale, the director now directly owns 11,245 shares of the company's stock, valued at $1,868,244.30. The trade was a 9.71 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 1,862 shares of company stock valued at $312,254 in the last 90 days. 0.16% of the stock is currently owned by insiders.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.